India, July 15 -- Agilus Diagnostics, in collaboration with Sebia, has launched the cutting-edge Anti-MCV (anti-mutated citrullinated vimentin) antibody test in India. This advanced test significantly enhances the early detection of rheumatoid arthritis (RA), especially in patients who test negative for conventional markers like anti-CCP (cyclic citrullinated peptides) and rheumatoid factor (RF).

Rheumatoid arthritis (RA), one of the most common autoimmune disorders, affects approximately 0.5-1% of the Indian population, with prevalence expected to rise due to increased awareness and improved diagnostic capabilities .

A groundbreaking antibody test developed bySebia, theanti-MCV (anti-mutated citrullinated vimentin)test, is redefining t...